CRISPR Therapy Raises Fetal Hemoglobin in Sickle Cell Disease - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

CRISPR Therapy Raises Fetal Hemoglobin in Sickle Cell Disease

An investigational Cas12a-edited stem cell treatment sharply boosted HbF and largely eliminated vaso-occlusive crises in an early trial

  • April 13, 2026

  • 2 min

Share

Original Source(s)

CRISPR Therapy Raises Fetal Hemoglobin in Sickle Cell Disease

  • April 13, 2026

Related Content

Matters arising in IJCD beyond minimally invasive pelvic exenteration: can single-port robotics overcome deep pelvic constraints?

Establishment and clinical performance evaluation of the thyroglobulin colloidal gold immunochromatographic assay

Editorial: Chimeric antigen receptor T cell therapies and bispecific antibodies in hematologic malignancies